Longitudinal PET/CT imaging with iodine (¹²⁴I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis

Ronald Landsa University of TN Graduate School of Medicine, Knoxville, TN, USAView further author information

Emily B. Martina University of TN Graduate School of Medicine, Knoxville, TN, USACorrespondence[email protected]
View further author information

Dustin Powellb Hendersonville Radiologic Consultants, Hendersonville, NC, USAView further author information

Alan Stuckeya University of TN Graduate School of Medicine, Knoxville, TN, USAView further author information

Bryan Whittlec University of Tennessee Medical Center, Knoxville, TN, USAView further author information

Spencer Guthried Attralus, Inc, San Francisco, CA, USAView further author information

Renju Raja University of TN Graduate School of Medicine, Knoxville, TN, USAView further author information

Stephen J. Kennela University of TN Graduate School of Medicine, Knoxville, TN, USAView further author information

Jonathan S. Walla University of TN Graduate School of Medicine, Knoxville, TN, USAView further author information

show all

References

Martin EB, Stuckey A, Powell D, et al. Clinical confirmation of Pan-Amyloid reactivity of radioiodinated peptide (124)I-p5 + 14 (at-01) in patients with diverse types of systemic amyloidosis demonstrated by PET/CT imaging. Pharmaceuticals (Basel). 2023; Apr 2116(4):629. doi:10.3390/ph16040629.
PubMedGoogle Scholar
Wechalekar AD, Sanchorawala V. Daratumumab in AL amyloidosis. Blood. 2022; Dec 1140(22):2317–2322. doi:10.1182/blood.2021014613.
PubMedGoogle Scholar
Muchtar E, Dispenzieri A, Leung N, et al. Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia. 2018; Oct32(10):2240–2249. doi:10.1038/s41375-018-0060-x.
PubMed Web of Science ®Google Scholar
Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med. 2015; Sep 17373(12):1106–1114. doi:10.1056/NEJMoa1504942.
PubMed Web of Science ®Google Scholar
Chacko L, Boldrini M, Martone R, et al. Cardiac magnetic Resonance-Derived extracellular volume mapping for the quantification of hepatic and splenic amyloid. Circ Cardiovasc Imaging. 2021; April 20,14(4). doi:10.1161/circimaging.121.012506.
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Longitudinal PET/CT imaging with iodine (¹²⁴I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Longitudinal PET/CT imaging with iodine (124I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Longitudinal PET/CT imaging with iodine (¹²⁴I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis